Prediction Case File
YouTubeEvaluation Complete

Friends! In This Video, Im going to analyze Marvell Technology Stock and discuss the risks and upside potential of MRVL stock

2 extracted signals · 2 resolved · 0 still active

The Patient Investor profile imageThe Patient InvestorIndependent analyst profile
Source published
08 Sept 2025, 22:36 UTC
Recorded by Tahlil Plus
18 May 2026, 20:23 UTC
Video preview for Friends! In This Video, Im going to analyze Marvell Technology Stock and discuss the risks and upside potential of MRVL stock
Source overview

AI-generated source summary

The analysis discusses Marvell Technology (MRVL) and Broadcom (AVGO), focusing on a divergence in their year-to-date performance. MRVL is down 42% year-to-date, while AVGO is up 44%. The analysis mentions partnerships of Broadcom with OpenAI for custom AI chips, and of Marvell with Amazon Web Services and Microsoft. MRVL's revenue growth is reported at 58% year-on-year and 6% quarter-on-quarter, coming from Data Center, Enterprise Networking, Carrier Infrastructure, and Consumer segments. The Automotive business was sold for $2.5 billion, which the company intends to reinvest in the Data Center business. The guidance for Q3 projects flat sequential revenue. MRVL is highly dependent on Amazon Web Services for 76% of its data center revenue. The analysis discusses the company's profitability trends, noting it is unprofitable. MRVL depends a lot on China which is risky. For non-GAAP, MRVL is profitable, with a 20 times earnings forward PE ratio.

AI-generated summary based on the source content.

Live evaluation

Signal outcomes at a glance

Evaluation Complete
Signals
2
Extracted from this source
Open
0
Still being tracked
Successful
2
Resolved successfully
Failed
0
Resolved unsuccessfully
Other
0
Cancelled, invalid or excluded
Resolved success
100%
2 resolved; open signals omitted
Extracted intelligence

Signals in this source

Case timeline

Evidence and evaluation progress

  1. Original source published

    The analyst published the original source item.

  2. First prediction resolved

    The first evaluable outcome in this case reached a terminal result.

  3. Case evaluation completed

    All evaluable predictions in this case reached terminal outcomes.

  4. Source recorded by Tahlil Plus

    The public source was preserved as the evidence record for this case.

  5. Market predictions extracted

    2 eligible signals linked to this case.

  6. Outcome tracking started

    Tahlil Plus began monitoring the extracted predictions.

Analyst snapshot

The Patient Investor

Platform-wide history, separate from this source evaluation.

Reliability
47.9
Tracked signals
355
Historical success
34.9%
View full analyst profile →
Methodology & disclosure

Tahlil Plus independently records and evaluates public market predictions. Extraction may be AI-assisted and results follow the Tahlil Plus methodology. This information is not financial advice.

Continue the evidence trail